This study will perform a proof of concept study to determine the optimal strategy for comprehensively characterizing somatic genetic events in individual tumors with a focus on grade II pediatric astrocytoma. We anticipate that these studies will determine the important oncogenes and tumor suppressor genes that drive pediatric low-grade glioma development. We also anticipate that an understanding of the molecular pathways disrupted by these mutations will guide the development of rational therapeutics for this disease. If successful, it will enable rapid follow-up with an extended characterization of larger numbers of tumors to identify the recurrent events that cause this disease.
Categories
Archives
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- November 2018
- September 2018
- June 2018
- May 2018
- January 2018
- December 2017
- November 2017
- August 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- February 2016
- November 2015
- September 2015
- August 2015
- June 2015
- April 2015
- March 2015
- February 2015
- January 2015
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- February 2014
- January 2014
- December 2013
- September 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- July 2012
- June 2012
- March 2012
- January 2012
- May 2011
- November 2010
- October 2010
- August 2010
- June 2010
- March 2010
- July 2009
- June 2009
- March 2009
- February 2009
- January 2009
- November 2008
- October 2008
- July 2008
- June 2008
- May 2007
- December 2006
- August 2006
- May 2006
- March 2006
- January 2006